CNS-Neurology News: Breaking CNS-Neurology News, Comments and Articles. - Page: 3

e-Therapeutics preliminary results for the year ended 31 January 2013.

14 May 2013 – e-Therapeutics plc (“e-Therapeutics”; AIM: ETX), the drug discovery and development company, today announces its preliminary results for the year ended 31 January 2013. Highlights of 2012/13 (* = events after the 31 January 2013 year end; **announced today) Lead cancer drug ETS2101 enters clinic US phase I trial started in patients with brain cancer...

Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors

NEW YORK, May 14, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, is pleased to announce the appointment of Professor Sir Michael Rawlins, MD, FRCP, FMedSci, to its board of directors.  Sir Michael is an internationally respected figure in the field of drug safety, clinical effectivenes...

Alcohol Addiction Treatment and Alcohol Rehab Announced by Recovery Associates Treatment Center

Recovery Associates announces alcohol addiction treatment and alcohol rehab program. The new program uses numerous tracks to help people find a new way of living. West Palm Beach, Florida (PRWEB) May 14, 2013 Alcohol addiction takes hold of an individual’s life and never gives it back. The more a person becomes dependent upon alcohol – whether it is beer or hard liquor – the more that indiv...

e-Therapeutics’ Preliminary Results for the Year Ended 31 January 2013

e-Therapeutics plc (“e-Therapeutics”; AIM: ETX), the drug discovery and development company, today announces its preliminary results for the year ended 31 January 2013. Highlights of 2012/13 (* = events after the 31 January 2013 year end; **announced today) Lead cancer drug ETS2101 enters clin...

Tel Aviv University researchers invent a method for repairing damaged peripheral nerves

Some parts of the body, like the liver, can regenerate themselves after damage. But others, such as our nervous system, are considered either irreparable or slow to recover, leaving thousands with a lifetime of pain, limited mobility, or even paralys...

NuPathe Announces First Quarter 2013 Financial Results and Operational Highlights

CONSHOHOCKEN, PA -- (Marketwired) -- 05/14/13 -- NuPathe Inc. (NASDAQ: PATH) today announced financial results for the quarter ended March 31, 2013, as well as recent operational highlights. "Approval of ZECUITY was a significant milestone for NuPathe as a company and offers a new treatment option for migraine patients, especially the millions of patients who suffer from migraine-related nausea...

Real-time in vivo analysis of T cell activation in the central nervous system using a genetically encoded calcium indicator

Marsilius Mues et al. have overcome previous obstacles precluding the expression of genetically encoded calcium indicators (GECIs) in immune cells by developing a new fluorescence resonance energy transfer–based GECI for the functional calcium imag...

RegeneRx Issues Letter to Sharholders

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today issued a letter to shareholders describing its future plans and initiatives. The letter may be viewed on RegeneRx’s home page or by following this link: http://www.regenerx.com/pdf/Letter-to-Shareholders_5-13-2013_Final.pdf The document will also be...

Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders

LAVAL, Quebec, May 13, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a live webcast of the company's annual meeting of shareholders.  The meeting and webcast will be held on Tuesday, May 21, 2013, at 9:00 a.m. ET at the International Headquarters, Laval Office:  2150 Saint Elzear Blvd. West, Laval Quebec, Cana...

Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society Congress

ROCKVILLE, Md., May 13, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that Eva Feldman, MD, PhD, principal investigator, will present updated Phase I data from the trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the Romanian Neurological Society Congress held in Bucharest,...

BioControl Medical Launches New Website to Deepen Patient, Family, Clinician Education on Its Investigational CardioFit® Therapy

BioControl Medical has unveiled a new corporate website that offers patients, family and clinicians a valuable educational resource on its CardioFit therapy for heart failure (HF), as well as the

Novartis: Partnering activity 2005-2013

Novartis announced over 265 partnering / licensing deals since 2005, with 23 deals in 2012 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology, infectives, central nervous system, genitourinary and respiratory diseases. Abstracted from: Partnering Deals and Alliances with Novartis The number of partnering, collaborative R&D and licensing deals announced...

Reversing paralysis with restorative gel: Researchers develop implant to regenerate nerves

(Medical Xpress)—Some parts of the body, like the liver, can regenerate themselves after damage. But others, such as our nervous system, are considered either irreparable or slow to recover, leaving thousands with a lifetime of pain, limited mobili...

New NIH funding to help researchers explore promising new approaches to cure stroke

Dr. Gregory Bix, Paul G. Blazer J. Professor of Stroke Research in the University of Kentucky Sanders-Brown Center on Aging and the UK departments of Anatomy and Neurobiology and Neurology, has received funding of $224,416 from the National Institute...

Breaking through the blood-brain barrier

To mark the European Month of the Brain, we look at one EU-funded project that has focussed efforts on drug delivery across the so-called blood-brain barrier. The blood-brain barrier (BBB), while preforming a key protective function, is now recognise...

Cells Aid In Scar Formation After Injury To Central Nervous System

By monitoring the behavior of a class of cells in the brains of living mice, neuroscientists at Johns Hopkins discovered that these cells remain highly dynamic in the adult brain, where they transform into cells that insulate nerve fibers and help fo...

AstraZeneca neurology news

NuPathe Announces Allowance of Additional U.S. Patent Application for NP201

CONSHOHOCKEN, PA -- (Marketwired) -- 05/13/13 -- NuPathe Inc. (NASDAQ: PATH) today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. Patent application 11/784,526 entitled "Implants for the Treatment of Dopamine Associated States." This application relates to methods for treating dopamine associated states (such as Parkinson's disease)...

How Nerve Wiring Self-Destructs Has Relevance To Diseases Of Peripheral And Central Nervous Systems

Many medical issues affect nerves, from injuries in car accidents and side effects of chemotherapy to glaucoma and multiple sclerosis. The common theme in these scenarios is destruction of nerve axons, the long wires that transmit signals to other pa...

Dietary Nicotine In Peppers May Reduce Risk Of Developing Parkinson's Disease

New research reveals that Solanaceae - a flowering plant family with some species producing foods that are edible sources of nicotine - may provide a protective effect against Parkinson's disease. The study appearing in Annals of Neurology, a journal...

“Traffic Jam” In Brain’s Neurons Could Be Cause Of Statin-Related Cognitive Decline

redOrbit Staff & Wire Reports – Your Universe Online Unusual swelling within some of the brain’s neurons might be responsible for the reversible memory loss and impaired thinking ability experienced by some patients who take cholesterol-lowering statins, researchers from the University of Arizona (UA) claim in a new study. The side effects, which have been observed by both physicians an...

The President's Impassioned Health Law Speech: 'We're Going To Keep Fighting'

President Barack Obama was unusually detailed in his defense of the law, emphasizing the scope of insurance coverage for many Americans. The Associated Press: Obama Declared Health Care Law 'Is Here To Stay' Caught between nervous Democrats and emboldened Republicans, President Barack Obama on Friday stepped up the sales pitch on his health care overhaul as the final elements of his top dome...

Obama declared health care law 'is here to stay'

WASHINGTON (AP) — Caught between nervous Democrats and emboldened Republicans, President Barack Obama on Friday stepped up the sales pitch on his health care overhaul as the final elements of his top domestic achievement go into effect. With his le...

Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal

LAVAL, Quebec, May 10, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has provided additional information related to the proposal to continue Valeant into British Columbia (the "Continuance") under the British Columbia Business Corporations Act (the "BCBCA"). The Continuance is being presented for shareholder approval at Valeant's...

Valeant Pharmaceuticals: Don't Take Profits Yet, Still Room To Grow In 2013

By Jeffrey To:Valeant Pharmaceuticals (NYSE:VRX) is a $22.5 billion pharmaceutical company that focuses on developing and distributing medicines for dermatology, neurology and other infectious diseases. It is trading at $72.81, near the top of its 52-week range of $42.47-$76.57 due to management's aggressive growth strategies. Valeant's expansion has been mainly driven by acquisitions, and I expec...